Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01427699 | A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes | PHASE2 | COMPLETED | 7 | — | — | Jun 30, 2011 | - | Feb 21, 2021 | 1 | Switzerland |
The safety and tolerability of T2-18C3 will be determined by observing patients for clinical adverse events, changes in vital signs, and changes in laboratory parameters such as hematology and chemistry.
| Arm | Type | Description |
|---|---|---|
| T2-18C3 therapeutic antibody | EXPERIMENTAL | 9 subjects will receive the T2-18C3 therapeutic antibody. |
| Name | Type | Description |
|---|---|---|
| T2-18C3 therapeutic antibody | DRUG | 1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses. |
Inclusion Criteria: * American Diabetes Association (ADA) diagnostic criteria for Type 2 Diabetes (T2D) * HbA1c \>7.0% and ≤ 10% * Current T2D duration \> 3 months at Screening * T2D and other diseases must be stable. Stable disease is defined as disease which did not require a change in medication...